<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632303</url>
  </required_header>
  <id_info>
    <org_study_id>GI 2031</org_study_id>
    <nct_id>NCT04632303</nct_id>
  </id_info>
  <brief_title>Early Palliative Care for Patients With Advanced Pancreatic Cancer.</brief_title>
  <acronym>EarlyCarePan</acronym>
  <official_title>Early Palliative Care for Patients With Advanced Pancreatic Cancer (EarlyCarePan).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inna Chen, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hillerod Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herning Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic adenocarcinoma is one of the deadliest cancers. Patients with pancreatic cancer&#xD;
      experience marked physical suffering, psychological distress and resource-demanding care at&#xD;
      the end-of-life. Therefore, an urgent need exists to evaluate the early specialized&#xD;
      palliative care model in a comparative study and across multiple care settings to define&#xD;
      quality of life and survival benefits in patients with pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic adenocarcinoma is one of the deadliest cancers. Approximately half of the patients&#xD;
      diagnosed with advanced pancreatic cancer die within 2 months from the diagnosis. Patients&#xD;
      eligible for systemic treatment have a median survival of less than one year and often&#xD;
      receive limited benefit from chemotherapy, usually with progression of disease after only a&#xD;
      few months of treatment. Patients with pancreatic cancer experience marked physical&#xD;
      suffering, psychological distress and resource-demanding care at the end-of-life.&#xD;
      Complications such as pain, fatigue, malnutrition, cachexia, exocrine insufficiency and&#xD;
      diagnosis itself lead to a poor quality of life and are associated with high rates of&#xD;
      depression and anxiety.&#xD;
&#xD;
      These invalidating symptoms are best alleviated by attachment to specialized palliative care&#xD;
      and by starting this support early in the course of the disease and not just in the terminal&#xD;
      phase. Early implementation of specialized palliative care is not a standard of care in&#xD;
      Denmark.&#xD;
&#xD;
      Thus, an urgent need exists to evaluate the early, integrated palliative care model in a&#xD;
      comparative study and across multiple care settings to define quality of life and survival&#xD;
      benefits for patients with pancreatic cancer in Denmark.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted mean change in global health status/QoL score at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adjusted mean change from baseline in global health status/QoL score from the EORTC QLQ-C30 questionnaire at 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival after randomization, defined as the time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted mean change from baseline in global health status/QoL at 6 and 24 weeks.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Adjusted mean change from baseline in global health status/QoL score from the EORTC QLQ-C30 questionnaire at 6 and 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted mean change from baseline in functional and symptom scales at 6, 12 and 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Adjusted mean change from baseline in functional and symptom scales from the EORTC QLQ-C30 questionnaire at 6, 12 and 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy dose intensity.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Chemotherapy dose intensity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Early Palliative Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline palliative care visit within 10 calendar days of registration/randomization and palliative care visits (either at clinic or at home) or phone calls (if a visit is not feasible) at least every four weeks throughout the patient's life. Referral to exercise training and nutritional specialist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Palliative care visit only upon request from attending oncologist(s) or patient/family.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Early Palliative Care</intervention_name>
    <description>Baseline palliative care visit Palliative care visits/calls at least every 4 weeks throughout life and additionally upon request Referral to exercise training Referral to nutritional specialist</description>
    <arm_group_label>Early Palliative Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult males and females (aged 18 and over)&#xD;
&#xD;
          -  Confirmed by cytology or histology incurable PDAC who are planned to receive medical&#xD;
             care for cancer in the first-line setting at the enrolling institution within â‰¤ 2&#xD;
             weeks&#xD;
&#xD;
          -  Written informed consent before any study procedures&#xD;
&#xD;
          -  Performance status: ECOG 0-2&#xD;
&#xD;
          -  Ability to read and respond to questions or able to complete questions with minimal&#xD;
             assistance required from an interpreter or family member&#xD;
&#xD;
          -  Planning to receive all medical care for cancer at the enrolling institution.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are already receiving care from the palliative care service are not&#xD;
             eligible for participation in the study&#xD;
&#xD;
          -  Exhibiting signs of overt psychopathology or cognitive dysfunction&#xD;
&#xD;
          -  Any medical condition that the Investigator considers significant to compromise the&#xD;
             safety of the patient or that impairs the interpretation of study assessments&#xD;
&#xD;
          -  Patient participating in another interventional study during the surveillance period.&#xD;
             This is only relevant for studies that might interfere with the intervention.&#xD;
             Participation in protocols related only to treatment will not preclude participation&#xD;
             in the present study. Cases of doubt will be settled by the protocol responsible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mette Nissen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev &amp; Gentofte Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mette Nissen, MD</last_name>
    <phone>+45 38686167</phone>
    <email>mette.nissen.01@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inna M Chen, MD</last_name>
    <phone>+45 38682898</phone>
    <email>Inna.Chen@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herlev &amp; Gentofte University Hospital, Denmark</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mette Nissen, MD</last_name>
      <phone>+45 38686167</phone>
      <email>mette.nissen.01@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Inna M Chen, MD</last_name>
      <phone>+45 38682898</phone>
      <email>Inna.Chen@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Inna Chen, MD</investigator_full_name>
    <investigator_title>Senior physician</investigator_title>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Early palliative care</keyword>
  <keyword>Specialized palliative care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

